Page 14 - Bryan Dunn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA December 28, 2020 GMT NEW YORK--(BUSINESS WIRE)--Dec 28, 2020-- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as a first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCL...

Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2021. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2020 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance … Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and li...

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of BAVENCIO ® as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who … – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicin...